According to an announcement by Mylan Inc. on Friday, its subsidiary Mylan Pharmaceuticals is selling 10 mg Alfuzosin Hydrochloride Extended-release Tablets, a generic version of Sanofi’s Uroxatral used for treating signs and symptoms of benign prostatic hyperplasia, or an enlarged prostate.
According to IMS Health, Uroxatral, or alfuzosin, brought in U.S. sales of approximately $241 million to the company for the 12 months ending on June 30, 2011. The drug was first approved in June 2003. At present, Mylan has 162 ANDAs representing $94.4 billion worth of annual sales awaiting FDA approval. Around 43 of the pending ANDAs are potential first-to-file opportunities.
In morning trading, shares of Mylan hiked 28 cents to $19.07.